A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Sol
A phase 1/2 trial of Tislelizumab, Bevacizumab in hepatocellular carcinoma and non-small-cell lung cancer, run by BeOne Medicines, now recruiting.
Overview
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06427941 by BeOne Medicines, with 630 participants planned, started 2024-07-23 and due to reach its primary completion in 2027-03-31. Interventions recorded: BGB-B2033, Tislelizumab, Bevacizumab. Conditions listed: Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
Shares Tislelizumab, Hepatocellular carcinoma, Small-cell lung cancer, Non-small-cell lung cancer.
- PersonJie Wang
Shares Tislelizumab, BeOne Medicines (formerly BeiGene), Small-cell lung cancer, Non-small-cell lung cancer.
- TrialComparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
Shares Tislelizumab, BeOne Medicines (formerly BeiGene), Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
Shares Tislelizumab, BeOne Medicines (formerly BeiGene), Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Adva
Shares Tislelizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus
- TrialTislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
- TrialA Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants